本页面由Tiger Trade Technology Pte. Ltd.提供服务

Enlivex Therapeutics Ltd.

1.07
-0.0200-1.83%
成交量:4.94万
成交额:5.33万
市值:2.54亿
市盈率:0.04
高:1.09
开:1.07
低:1.06
收:1.09
52周最高:2.10
52周最低:0.6600
股本:2.37亿
流通股本:2.35亿
量比:0.48
换手率:0.02%
股息:- -
股息率:- -
每股收益(TTM):25.48
每股收益(LYR):25.48
净资产收益率:126.17%
总资产收益率:-0.80%
市净率:0.13
市盈率(LYR):0.04

数据加载中...

2026/03/25

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2026/03/13

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2025/12/30

SEC问询函

Form CORRESP - Correspondence
2025/05/09

SEC问询函

Form CORRESP - Correspondence
2025/05/01

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/04/30

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/10

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/05/03

SEC问询函

CORRESP [Cover] - Correspondence
2022/04/29

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/06/04

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2021/04/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/10

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2021/02/09

[补充]招股说明书

FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses
2020/08/14

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/05/18

财报披露

6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/04/30

年度报告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2020/04/13

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/18

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]
2020/03/05

非美公司披露报告

Report of foreign issuer [Rules 13a-16 and 15d-16]